title: Long lasting response to second-line everolimus in kidney cancer.
abstract: In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus.
authors.affiliation: Antonella Virtuoso, Tania Policastro, Michela Izzo, Piera Federico, Carlo Buonerba, Pasquale Rescigno, Giuseppe Di Lorenzo, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, 80131 Naples, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Virtuoso
authors.forename: Tania
authors.initials: T
authors.lastname: Policastro
authors.forename: Michela
authors.initials: M
authors.lastname: Izzo
authors.forename: Piera
authors.initials: P
authors.lastname: Federico
authors.forename: Carlo
authors.initials: C
authors.lastname: Buonerba
authors.forename: Pasquale
authors.initials: P
authors.lastname: Rescigno
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
keywords: Everolimus (RAD001); Metastatic renal cell carcinoma; Progression-free survival; Sunitinib